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This is the most comprehensive review to date about the hematological aspects of COVID-19 including the 
latest evidence of the morphological and clinical manifestations with emphasis on the distinct 
coagulopathy associated with the disease.
This review highlights the paramount importance of hematological parameters such as inflammatory 
markers, D-dimer level and absolute lymphocyte count in defining prognostic groups and monitoring 
response to therapy in COVID-19.
The emphasis on the increased thrombotic risk and the importance of anticoagulation in COVID-19 is of 
specific relevance to clinicians.
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Abstract: 
Emerging data from the management of patients with Coronavirus Disease 2019 (COVID-19) suggests 
multisystemic involvement, including the hemopoietic system. The hematological manifestations of 
COVID-19 include blood count anomalies notably lymphopenia and neutrophilia which are of prognostic 
significance. Hyperferritinemia and elevated lactate dehydrogenase have also been associated with 
increased mortality. Furthermore, there is considerable evidence of a distinct coagulopathy associated 
with COVID-19 characterised by elevated D-dimers and an increased risk of thrombotic events. This 
comprehensive review summarises the latest evidence from published studies and discusses the 
implications of the various hematological manifestations of COVID-19 with a view to guiding clinical 
management and risk stratification in this rapidly evolving pandemic.
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Introduction:
Since the first cases of the Coronavirus Disease 2019 (COVID-19) were reported in Wuhan, China in 
December 2019, the disease has rapidly evolved into a pandemic with over 3 million confirmed cases and 
200,000 deaths in 185 countries as of April 2020.[1] COVID-19 is caused by the novel Severe Acute 
Respiratory Syndrome coronavirus 2 (SARS-C  oV-2), a betacoronavirus which is transmitted mainly via 
droplets and contaminated surfaces.[2,3] Over the past 2 decades, two other severe respiratory diseases, 
Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS),  have been 
caused by betacoronaviruses, SARS-CoV and MERS-CoV respectively in humans.[4] SARS-CoV-2 shares 
79% sequence identity with SARS-CoV, the virus responsible for the Severe Acute Respiratory Syndrome 
(SARS) outbreak 2002-2004.[5,6] While much of the pathogenesis of COVID-19 remains to be unravelled, 
it is known that SARS-CoV-2, like SARS-CoV, binds to host cells via its receptor, angiotensin converting 
enzyme 2 (ACE2), which is expressed across a wide range of human cell types including lung type II 
pneumocytes and the endothelium of blood vessels.[7,8] The clinical spectrum of COVID-19 ranges from 
asymptomatic to severe pneumonia or acute respiratory distress syndrome (ARDS) resulting in respiratory 
failure and death.[9,10] While COVID-19 is considered to be primarily a respiratory infection, there is 
increasing evidence of multi-systemic complications of the disease. With more case series being 
published, a number of hematological manifestations have been now come to light. The key 
hematological abnormalities of COVID-19 are summarised in Table 1.
Blood count abnormalities
The most commonly reported blood count abnormality is lymphopenia which occurs in 35%-83% of 
patients. [11–13] Lymphopenia is also more frequent and the absolute lymphocyte count much lower in 
severe cases of COVID-19. [14–16] In one study of hematological parameters in hospitalised COVID-19 
patients in Singapore, the median nadir of the absolute lymphocyte count (ALC) was significantly lower in 
patients requiring admission to Intensive Care Unit (ICU) (0.4 vs 1.2 x109/L) as was neutrophilia (11.6 vs 
3.5 x109/L). [13] Another study from Wuhan revealed a similar pattern with more severe cases having 
higher neutrophil (4.3 vs 3.2 ×10⁹/L ; P < 0.001) counts, lower lymphocytes counts (0.8 vs 1.0 ×10⁹/L ; P < 
0.001), higher Neutrophil-to-Lymphocyte Ratio (NLR) (5.5 vs 3.2; P < 0.001) as well as lower percentages 
of monocytes, eosinophils and basophils.[17] In addition to a significant reduction in both CD4+ and CD8+ 
T lymphocyte subsets in COVID-19 patients, severe cases had much lower CD8+ lymphocytes and a 
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Mild thrombocytopenia (100-150 x109/L) has been reported in up to 20-36% of COVID-19 cases [11–13] 
however, severe thrombocytopenia (<50 x109/L) is unusual. In a case series of patients admitted to an 
intensive care unit in Wuhan, a platelet count of <100 x109/L was observed in only 5% of patients.[14] 
Similar findings were reported in a French cohort study with mild thrombocytopenia identified in about a 
quarter of COVID-19 patients on admission to hospital and this was independently predictive of the risk of 
admission to ICU, mechanical ventilation or death.[19] Furthermore, data from multiple studies suggest 
that anemia is not a prominent feature of COVID-19 even in severe cases. [11,13,14] A case series of 
autoimmune haemolytic anaemia occurring in COVID-19 patients was recently published but about half of 
the patients in this study had an underlying haematological disorder known to be associated with 
autoimmune haemolysis.[20]
Peripheral blood film and morphological features
Examination of the peripheral blood smear remains a crucial part of the hematological assessment and 
can often aid the diagnosis of many conditions. Notable features reported in COVID-19 cases include an 
increased frequency of reactive and plasmacytoid lymphocytes, [13][21] significant left-shifted 
granulopoiesis with hypergranular, occasionally vacuolated neutrophils [22] and leucoerythroblastic 
features [23]. The presence of schistocytes or red cell fragments has not been reported. Furthermore, 
from the experience of the authors, bone marrow hemophagocytosis can be a feature of severe COVID-19 
and this has been observed in a small number of patients managed at New Cross Hospital, 
Wolverhampton, United Kingdom. The bone marrow aspirate from one of the patients is shown in Figure 
1. This pathologic finding corroborates recent reports of cases of COVID-19 meeting the clinical criteria for 
secondary Hemophagocytic Lymphohistiocytosis (sHLH). [24,25] 
Other blood markers
Alongside other acute phase markers such as C-Reactive Protein (CRP), procalcitonin and Erythrocyte 
Sedimentation Rate (ESR), an elevated ferritin has been associated with increased mortality in COVID-19. 
[17,26,27]. Significant elevation of Lactate Dehydrogenase (LDH) has also been observed in patients with 
severe disease.[13] 
COVID-19 Cytokine Storm and hematological hyperinflammatory syndromes
Observations from the clinical, biochemical and serological manifestations of COVID-19 strongly support 
an immunological basis for the severe manifestations of the disease. [27] The marked elevation of pro-
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COVID-19,[28][29][30] point to a state of disordered and exaggerated immune response to SARS-CoV-2 
infection, often referred to as the “cytokine storm”. Several complex pathways have been implicated in 
the pathogenesis of COVID-19 cytokine storm including the Renin-Angiotensin-Aldosterone system 
(RAAS), JAK/STAT and Complement activation pathways.[29,31,32] Furthermore, parallels can be drawn 
with the Cytokine Release Syndrome (CRS) associated with Chimeric Antigen Receptor (CAR) T cell therapy 
and hemophagocytic lymphohistiocytosis (HLH), which are both states of immune dysregulation and 
hyperinflammation frequently encountered by haematologists. CRS, thought to be due to T cell activation, 
is characterised by marked elevation of inflammatory markers and cytokines notably IL-6, fever, 
hypotension and respiratory insufficiency following the infusion of CAR T cells or other immune 
therapies.[33,34] Similarly, HLH is characterised by uncontrolled activation of cytotoxic T lymphocytes, 
natural killer cells and macrophages resulting in hypercytokinemia and immune-mediated organ damage. 
[35] The aetiology of HLH may be primary (as a result of inherited genetic mutations) or secondary to 
other conditions including viral infections and often presents with features of CRS in addition to 
histological evidence of hemophagocytosis, cytopenias, hyperferritinemia, organomegaly, coagulopathy 
and multi-organ failure.[36]  Secondary HLH (sHLH) is probably an under-recognised feature of severe 
COVID-19. A recent case series of 4 autopsies of patients who died from COVID-19 published as a preprint, 
[25] reported histologic evidence of haemophagocytosis within pulmonary and hilar lymph nodes in the 
majority of cases. However, in a study of 40 critically-ill COVID-19 patients admitted to an intensive care 
unit, only 3 (7.5%) met the cut off for sHLH using the HScore.[24] This observation was most likely due to 
the absence of certain cardinal features such as organomegaly and hypofibrinogenemia in the majority of 
COVID-19 patients, possibly indicating a distinct mechanism of SARS-CoV-2-associated sHLH. 
Understanding the link between CRS, HLH and COVID-19 cytokine storm is crucial because this would 
expedite the repurposing of therapies for severe COVID-19. Indeed, early clinical studies have indicated 
that certain immunomodulatory therapies used in CRS and sHLH such as dexamethasone [37], 
tocilizumab[38] and anakinra [39] may be effective in severe COVID-19.
Given the pivotal role of IL-6 signalling in CRS and its prognostic significance in COVID-19,[40] there has 
been considerable interest in the therapeutic potential of the IL-6 receptor antagonist, tocilizumab. Two 
separate case reports of the use of tocilizumab in acute chest syndrome of Sickle cell disease precipitated 
by COVID-19 reported rapid responses in an adult[41] and a teenager[42]. Tocilizumab administration also 
resulted in clinical improvement in a patient with COVID-19 and multiple myeloma.[43] A recently 
published retrospective cohort study of patients treated with tocilizumab, the largest to date, observed a 









compared with controls.[38] Several randomised clinical trials of tocilizumab are ongoing and the results 
of these studies are eagerly awaited. 
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COVID-19-Associated Coagulopathy (CAC)
Recent data emerging from the management of patients with COVID-19 suggests an increased thrombotic 
tendency. Approximately one-third of patients with COVID-19 had CT scan evidence of pulmonary 
embolism (PE) in a French study.[44] Notably, two thirds of the patients without PE in this cohort also had 
elevated D-dimers with a higher cut off value of 2660 µg/L being more predictive of PE in this cohort. A 
Dutch study of COVID-19 patients admitted to ICU similarly identified a 31% incidence of thrombotic 
events including PE, Deep Vein Thrombosis (DVT) and ischaemic strokes despite all patients having 
received prophylactic anticoagulation.[45] A retrospective study of COVID-19 patients admitted to ICU 
identified DVT in 25% with advanced age, lower lymphocyte counts and elevated D-dimers being 
significant risk factors.[46] The prognostic importance of D-dimer testing was further demonstrated in a 
prospective study of hospitalised COVID-19 patients which revealed that significantly higher D-dimer and 
prolonged Prothrombin Time (PT) were associated with a higher probability of mortality.[47] In a study 
investigating prolonged Activated Partial Thromoplastin Time (APTT) in patients with COVID-19, the lupus 
anticoagulant was detected in 91%. [48] In addition, markedly elevated Von Willebrand Factor (VWF) 
levels (VWF:antigen-555%, VWF:activity-520%) and Factor VIII (clotting activity of 369%) in addition to 
antiphospholipid antibodies were observed in a patient with severe COVID-19.[49] Taken together, these 
findings strongly support the existence of a syndrome of COVID-19-associated coagulopathy characterised 
by derangements in clotting tests (PT and APTT), elevated D-dimer and an increased thrombotic tendency. 
In a study comparing coagulation parameters in hospitalised COVID-19 patients, 15 (71.4%) of non-
survivors met the International Society on Thrombosis and Haemostasis (ISTH) criteria for overt 
Disseminated Intravascular Coagulation (DIC) compared with 1(0.6%) of survivors.[47] Therefore, the ISTH 
DIC scoring system which includes platelet count, fibrinogen, D-Dimer and prothrombin time (Table 2) is 
likely to be a useful prognostic tool for COVID-19-associated coagulopathy. The coagulopathy of COVID-19 
appears to be distinct from DIC due to other causes in elevated fibrinogen,[50] modest prolongation of 
the APTT and the absence of schistocytes on the blood film.[51] Interestingly, despite the derangements 
in coagulation tests, abnormal bleeding is unusual.[52,53] Furthermore, much of the data for 
coagulopathy in COVID-19 has been from hospitalised patients with the severe form of the disease. It is 
yet unclear but unlikely that patients with mild COVID-19 are at increased risk of thrombosis.  
Discussion:
While still not fully understood, the immune response to SARS-CoV-2 is thought to be two-phased; an 









This article is protected by copyright. All rights reserved
proportion of individuals is ineffective, leading to uncontrolled viral replication, triggering an exaggerated 
innate immune response which results in multi-organ failure in the most severe cases.[54,55] The 
dysregulated secretion of pro-inflammatory cytokines perpetuates hyperinflammation and is thought to 
be the basis of the cytokine storm in COVID-19. This two-phased model of the immune response would 
probably account for the lack of efficacy of some immunosuppressive therapies in non-severe cases of the 
disease.[37] Furthermore, aging is generally associated with diminished adaptive immune function and an 
exaggerated innate immune response to pathogens, notably a shift towards myelopoiesis and neutrophil 
accumulation in animal models. [56,57] These age-related changes in the immune system may, at least 
partly, explain the increased mortality of COVID-19 among the elderly. A lot is still not known about the 
marked difference between immune responses to SARS-CoV-2 between individuals and it is likely that 
genetic and environmental factors also play a role. Of particular interest is the association between 
certain ABO blood group genotypes and the likelihood of severe COVID-19. In a recently published 
genomewide association study, Blood group A and a few other Single Nucleotide Polymorphisms (SNPs) 
were associated with an increased risk of COVID-19-induced respiratory failure (Blood group O was 
apparently protective).[58] Interestingly, Blood group A has also been shown to be associated with 
increased odds of thromoboembolic and cardiovascular events.[59,60] These findings are hardly 
surprising because blood group A individuals (as well as other non-O blood groups) are known to have 
higher plasma Von Willebrand levels [61,62] and ABO blood group antigens have innate immune 
functions.[63] 
Currently, the evidence base for the clinical management of COVID-19 is mostly limited to case series and 
other relatively small observational studies of hospitalised patients. Despite the limitations, these studies 
provide useful insight into the manifestations of the disease. Similar to findings in SARS patients,[64] 
lymphopenia is the most commonly reported hematological abnormality in COVID-19 and recent data 
shows that it can be predictive of disease severity. However, as an isolated finding, lymphopenia is not 
specific for COVID-19 and is a common finding in the elderly. The predictive utility of lymphopenia is likely 
to be improved when the trend is considered alongside other parameters particularly the presence of 
neutrophilia  a higher neutrophil-lymphocyte ratio. Furthermore, assessments of lymphocyte subsets in 
COVID-19 patients have revealed a significant reduction in T and B lymphocytes along with Natural Killer 
(NK) cells, more marked among patients with severe disease.[17,28,65] Of particular interest was the 
finding of reduced regulatory T cells (Treg) in severe cases.[28] The precise mechanism of the 
development of lymphopenia in COVID-19 is not known but lymphocytes have been shown to express 
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of lymphocytes away from the peripheral blood to the lungs or other sites of infection may also play a 
role.[69] The neutrophilia observed in severe cases of COVID-19 is most likely a response to the cytokine 
storm which has been implicated in the most severe manifestations of the disease. Furthermore, 
significant elevations of acute-phase markers such as ferritin, CRP and procalcitonin have been associated 
with mortality from COVID-19 and these biomarkers are positively correlated with increased pro-
inflammatory cytokines such as Interlukin-6 and TNF-α.[26,28] Therefore, serial monitoring of these 
markers may facilitate early therapeutic intervention with experimental immunomodulatory agents. 
With recent reports of thrombotic complications in patients with COVID-19, there is increasing 
recognition of a distinct coagulopathy associated with COVID-19. The underlying mechanism is likely to be 
multifactorial including direct endothelial damage from SARS-CoV-2 or immune cells,[70] inflammatory 
cytokine-induced activation of the coagulation cascade[71], the development of antiphospholipid 
antibodies and an increase in acute phase pro-coagulants such as Factor VIII and fibrinogen.   
Derangements of coagulation reported among COVID-19 cases include prolongation of the PT and to a 
lesser extent, APTT. The relative shortening of the APTT is possibly due to significantly increased levels of 
Factor VIII.  Furthermore, hyperviscosity has been postulated as a possible link between 
hyperinflammation and coagulopathy following the association of an increased risk of arterial and venous 
thromboses with plasma viscosity levels greater than 3.5 centipoise (twice the upper limit of normal) in a 
study of ICU patients with COVID-19.[72] However, the hyperviscosity in COVID-19 is most likely due to 
the marked elevation of acute phase proteins and does not completely explain the severe thrombophilic 
state which is out of proportion to other conditions associated with comparable degrees of plasma 
viscosity. Plasma exchange may nevertheless be beneficial as this could theoretically replace most of the 
elevated circulating cytokines and pro-coagulant factors.  The use of convalescent plasma may, in 
addition, provide neutralising antibodies against SARS-CoV-2 and a small-scale clinical trial has reported 
modest but encouraging results in severely-ill but not in critical COVID-19 patients.[73] The lack of efficacy 
in the latter group probably reflects the irreversibility of end-organ damage from hyperinflammation and 
the relatively minimal contribution from SARS-CoV-2 at this stage of the disease.
From a prognostic perspective, D-dimers appear to be the most useful coagulation parameter as 
progressive increase in D-Dimer level is associated with the development of severe disease and in-hospital 
mortality. [47] Therefore, serial monitoring of D-dimers can be a useful biomarker of clinical severity in 
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Management of Covid-19 associated coagulopathy
The mainstay of the management of CAC is prevention as well as early recognition and treatment of 
thrombotic events. Regarding the prevention of thrombotic events in hospitalised COVID-19 patients, 
evidence from China suggests that prophylactic heparin reduces mortality in high-risk patients.[52] 
Consequently, the recently published ISTH interim guidance recommends prophylactic anticoagulation 
with low molecular weight heparin (LMWH) for all hospitalised patients with COVID-19. [74] LMWH is the 
preferred anticoagulant as it does not interfere with the PT or APTT and the anti-inflammatory properties 
of heparins could indeed provide additional benefits in this setting.[75] Unfractionated heparin with anti-
Xa monitoring may be a useful alternative given its widespread use in the intensive care setting but close 
monitoring for the development of Heparin-Induced Thrombocytopenia (HIT) is recommended. 
Furthermore, since CAC is not commonly associated with a bleeding phenotype, anticoagulation is 
recommended regardless of derangements in the PT or APTT, provided other contraindications are 
excluded. Moreover, transfusion of blood products such as fresh frozen plasma (FFP) or cryoprecipitate to 
correct abnormal clotting parameters in the absence of bleeding is not recommended as this could be 
detrimental. Cautious transfusion of blood products is however indicated in bleeding patients. Given the 
histological finding of widespread fibrin deposition consistent with microvascular thrombosis reported in 
COVID-19 cases, [76] clinical trials are needed to evaluate the efficacy of experimental fibrinolytic 
therapies such as tissue plasminogen activator (tPA).[77] 
Recommendations and conclusions
In view of the reported high incidence of thrombotic events despite prophylactic anticoagulation in 
critically ill patients with COVID-19, [53,78,79] there is a strong argument for intensification of 
anticoagulation in this setting but the benefit of this strategy remains to be determined due to the lack of 
clinical trial data. While there is currently insufficient evidence to recommend therapeutic anticoagulation 
in all patients with COVID-19 in the absence of Venous Thromboembolism (VTE), an individualised risk-
based approach to intensification of anticoagulation may be considered. 
In summary, severe COVID-19 represents a state of immune dysregulation and hyperinflammation which 
account for the multisystemic manifestations, including the hematological anomalies associated with the 
disease. Therefore, monitoring of hematological parameters such as the absolute lymphocyte count, 
neutrophil-to-lymphocyte ratio and D-dimers can offer prognostic insight in the management of COVID-19 
and will help with early identification of the high risk group of patients requiring more intensive care. In 
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molecular weight heparin is recommended for all hospitalised patients with the disease and clinical trials 
are needed to investigate the role of more intensive anticoagulation and other experimental therapies. In 
addition, further translational research is needed to fully unravel the pathogenesis of COVID-19, 
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Reactive and Plasmacytoid lymphocytes on blood film 
Elevated ferritin† 
COVID-19-associated coagulopathy  
Elevated D-dimers† 
Prolonged PT†  
Prolonged APTT 
Elevated fibrinogen 
†features of prognostic significance (see supplementary table for the relevant study data) 
 
Table 1: Hematologic manifestations of COVID-19. LDH-Lactate Dehydrogenase, PT-Prothromin 





















Elevated fibrin-related marker eg D-dimer 
Not elevated 
Moderate increase (1-10x ULN) 




Prolonged Prothrombin Time 
<3 seconds above ULN 
>3-<6 seconds above ULN 










Total score of ≥5: compatible with overt DIC  
 
 
Table 2: ISTH Criteria for overt DIC has prognostic significance in COVID-19-related coagulopathy 
(modified from [80] ). ULN-Upper limit of normal.  
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